Stock Events

Heidelberg Pharma 

€3.09
0
+€0+0% Friday 20:41

Statistics

Day High
3.09
Day Low
3.04
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
145.02M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

22MarExpected
Q4 2021
Q2 2022
Q3 2022
Q4 2022
Q2 2023
Q3 2023
Next
-0.21
-0.15
-0.1
-0.04
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HPHA.F. It's not an investment recommendation.

About

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors; HDP-XX for the treatment of solid/hematological tumors; MGTA-ATACs for HSCs, conditioning programs to treat blood cancers/genetic diseases; and TAK-ATACs for oncology. It is also developing TLX250-CDx, a diagnostic antibody for diagnosing renal cancer that is in Phase III trials; urothelial carcinoma or bladder cancer, which is in Phase II study; and triple-negative breast cancer that is in Phase II study. In addition, the company develops TLX250 (girentuximab), a diagnostic antibody, which is in Phase II study for patients with advanced clear cell renal cell carcinoma; RHB-107, an oral serine protease inhibitor that is in Phase II/III study to treat COVID-19, as well as for the treatment of advanced cholangiocarcinoma; and LH011 for pancreatic cancer. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.
Show more...
CEO
Prof. Andreas Pahl
Employees
101
Country
DE
ISIN
DE000A11QVV0
WKN
000A11QVV

Listings